nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolterodine—CYP2C9—Bexarotene—hematologic cancer	0.0316	0.049	CbGbCtD
Tolterodine—CYP2D6—Lomustine—hematologic cancer	0.0269	0.0416	CbGbCtD
Tolterodine—CYP2C9—Idarubicin—hematologic cancer	0.0262	0.0406	CbGbCtD
Tolterodine—CYP2D6—Idarubicin—hematologic cancer	0.024	0.0371	CbGbCtD
Tolterodine—CYP2C19—Bortezomib—hematologic cancer	0.0233	0.0361	CbGbCtD
Tolterodine—CYP2D6—Hydroxyurea—hematologic cancer	0.0204	0.0315	CbGbCtD
Tolterodine—CYP2C19—Thalidomide—hematologic cancer	0.0203	0.0314	CbGbCtD
Tolterodine—CYP2C9—Bortezomib—hematologic cancer	0.0194	0.03	CbGbCtD
Tolterodine—CYP2C19—Teniposide—hematologic cancer	0.0194	0.03	CbGbCtD
Tolterodine—CYP3A4—Bexarotene—hematologic cancer	0.0184	0.0285	CbGbCtD
Tolterodine—CYP2C19—Ifosfamide—hematologic cancer	0.0179	0.0277	CbGbCtD
Tolterodine—CYP2D6—Bortezomib—hematologic cancer	0.0177	0.0274	CbGbCtD
Tolterodine—CYP3A4—Busulfan—hematologic cancer	0.0171	0.0265	CbGbCtD
Tolterodine—CYP3A4—Lomustine—hematologic cancer	0.0171	0.0265	CbGbCtD
Tolterodine—CYP2C19—Imatinib—hematologic cancer	0.0171	0.0264	CbGbCtD
Tolterodine—CYP2C9—Thalidomide—hematologic cancer	0.0169	0.0261	CbGbCtD
Tolterodine—CYP2C9—Teniposide—hematologic cancer	0.0161	0.0249	CbGbCtD
Tolterodine—CYP3A4—Thiotepa—hematologic cancer	0.0152	0.0236	CbGbCtD
Tolterodine—CYP2C9—Ifosfamide—hematologic cancer	0.0149	0.023	CbGbCtD
Tolterodine—CYP2C9—Imatinib—hematologic cancer	0.0142	0.022	CbGbCtD
Tolterodine—CYP2D6—Imatinib—hematologic cancer	0.013	0.0201	CbGbCtD
Tolterodine—CYP2C9—Nilotinib—hematologic cancer	0.0129	0.02	CbGbCtD
Tolterodine—CYP3A4—Methoxsalen—hematologic cancer	0.0119	0.0183	CbGbCtD
Tolterodine—CYP2D6—Nilotinib—hematologic cancer	0.0118	0.0183	CbGbCtD
Tolterodine—CYP2D6—Vinorelbine—hematologic cancer	0.0117	0.0181	CbGbCtD
Tolterodine—CYP3A4—Bortezomib—hematologic cancer	0.0113	0.0175	CbGbCtD
Tolterodine—CYP2C19—Prednisone—hematologic cancer	0.0113	0.0174	CbGbCtD
Tolterodine—CYP3A4—Daunorubicin—hematologic cancer	0.0108	0.0167	CbGbCtD
Tolterodine—CYP3A4—Cytarabine—hematologic cancer	0.00951	0.0147	CbGbCtD
Tolterodine—CYP3A4—Teniposide—hematologic cancer	0.00937	0.0145	CbGbCtD
Tolterodine—CYP3A4—Ifosfamide—hematologic cancer	0.00865	0.0134	CbGbCtD
Tolterodine—CYP3A4—Imatinib—hematologic cancer	0.00826	0.0128	CbGbCtD
Tolterodine—CYP3A4—Ruxolitinib—hematologic cancer	0.00778	0.012	CbGbCtD
Tolterodine—CYP3A4—Nilotinib—hematologic cancer	0.00751	0.0116	CbGbCtD
Tolterodine—CYP3A4—Vinorelbine—hematologic cancer	0.00744	0.0115	CbGbCtD
Tolterodine—CYP2C9—Cisplatin—hematologic cancer	0.00723	0.0112	CbGbCtD
Tolterodine—CYP2D6—Vinblastine—hematologic cancer	0.00721	0.0112	CbGbCtD
Tolterodine—CYP2C19—Dexamethasone—hematologic cancer	0.00703	0.0109	CbGbCtD
Tolterodine—CYP3A4—Triamcinolone—hematologic cancer	0.00681	0.0105	CbGbCtD
Tolterodine—CYP3A4—Dasatinib—hematologic cancer	0.00663	0.0103	CbGbCtD
Tolterodine—CYP3A4—Mitoxantrone—hematologic cancer	0.00655	0.0101	CbGbCtD
Tolterodine—CYP2C9—Dexamethasone—hematologic cancer	0.00584	0.00904	CbGbCtD
Tolterodine—CYP3A4—Betamethasone—hematologic cancer	0.00584	0.00904	CbGbCtD
Tolterodine—CYP3A4—Prednisolone—hematologic cancer	0.00576	0.00892	CbGbCtD
Tolterodine—CYP3A4—Prednisone—hematologic cancer	0.00544	0.00842	CbGbCtD
Tolterodine—CYP2D6—Dexamethasone—hematologic cancer	0.00534	0.00827	CbGbCtD
Tolterodine—CYP3A4—Irinotecan—hematologic cancer	0.00516	0.00799	CbGbCtD
Tolterodine—CYP3A4—Vinblastine—hematologic cancer	0.00459	0.0071	CbGbCtD
Tolterodine—CYP3A4—Vincristine—hematologic cancer	0.00451	0.00698	CbGbCtD
Tolterodine—CYP2D6—Doxorubicin—hematologic cancer	0.00443	0.00686	CbGbCtD
Tolterodine—CYP3A4—Etoposide—hematologic cancer	0.00413	0.0064	CbGbCtD
Tolterodine—CYP3A4—Dexamethasone—hematologic cancer	0.0034	0.00526	CbGbCtD
Tolterodine—CYP3A4—Doxorubicin—hematologic cancer	0.00282	0.00436	CbGbCtD
Tolterodine—Disopyramide—SLC22A1—hematologic cancer	0.000416	0.373	CrCbGaD
Tolterodine—Chlorphenamine—SLC22A1—hematologic cancer	0.000304	0.272	CrCbGaD
Tolterodine—Fesoterodine—ABCB1—hematologic cancer	0.000271	0.243	CrCbGaD
Tolterodine—Pain—Gemcitabine—hematologic cancer	0.000128	0.000499	CcSEcCtD
Tolterodine—Constipation—Gemcitabine—hematologic cancer	0.000128	0.000499	CcSEcCtD
Tolterodine—Abdominal pain—Ifosfamide—hematologic cancer	0.000128	0.000499	CcSEcCtD
Tolterodine—Anaphylactic shock—Etoposide—hematologic cancer	0.000128	0.000499	CcSEcCtD
Tolterodine—Asthenia—Thiotepa—hematologic cancer	0.000128	0.000498	CcSEcCtD
Tolterodine—Vertigo—Triamcinolone—hematologic cancer	0.000128	0.000498	CcSEcCtD
Tolterodine—Diarrhoea—Vinorelbine—hematologic cancer	0.000128	0.000497	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Cisplatin—hematologic cancer	0.000127	0.000496	CcSEcCtD
Tolterodine—Infection—Etoposide—hematologic cancer	0.000127	0.000495	CcSEcCtD
Tolterodine—Hypersensitivity—Thalidomide—hematologic cancer	0.000127	0.000495	CcSEcCtD
Tolterodine—Feeling abnormal—Mitoxantrone—hematologic cancer	0.000127	0.000494	CcSEcCtD
Tolterodine—Feeling abnormal—Irinotecan—hematologic cancer	0.000127	0.000494	CcSEcCtD
Tolterodine—Dizziness—Bortezomib—hematologic cancer	0.000126	0.000492	CcSEcCtD
Tolterodine—Anaphylactic shock—Prednisolone—hematologic cancer	0.000126	0.000492	CcSEcCtD
Tolterodine—Oedema—Prednisolone—hematologic cancer	0.000126	0.000492	CcSEcCtD
Tolterodine—Dysuria—Methotrexate—hematologic cancer	0.000126	0.000491	CcSEcCtD
Tolterodine—Gastrointestinal pain—Mitoxantrone—hematologic cancer	0.000126	0.00049	CcSEcCtD
Tolterodine—Gastrointestinal pain—Irinotecan—hematologic cancer	0.000126	0.00049	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Methotrexate—hematologic cancer	0.000125	0.000488	CcSEcCtD
Tolterodine—Tachycardia—Etoposide—hematologic cancer	0.000125	0.000487	CcSEcCtD
Tolterodine—Abdominal pain—Vincristine—hematologic cancer	0.000125	0.000486	CcSEcCtD
Tolterodine—Phenprocoumon—ALB—hematologic cancer	0.000124	0.112	CrCbGaD
Tolterodine—Dry skin—Doxorubicin—hematologic cancer	0.000124	0.000482	CcSEcCtD
Tolterodine—Asthenia—Thalidomide—hematologic cancer	0.000124	0.000482	CcSEcCtD
Tolterodine—Feeling abnormal—Gemcitabine—hematologic cancer	0.000123	0.000481	CcSEcCtD
Tolterodine—Dizziness—Vinorelbine—hematologic cancer	0.000123	0.000481	CcSEcCtD
Tolterodine—Tachycardia—Prednisolone—hematologic cancer	0.000123	0.00048	CcSEcCtD
Tolterodine—Hypersensitivity—Carmustine—hematologic cancer	0.000122	0.000475	CcSEcCtD
Tolterodine—Diarrhoea—Thiotepa—hematologic cancer	0.000122	0.000475	CcSEcCtD
Tolterodine—Abdominal pain—Irinotecan—hematologic cancer	0.000121	0.000474	CcSEcCtD
Tolterodine—Abdominal pain—Mitoxantrone—hematologic cancer	0.000121	0.000474	CcSEcCtD
Tolterodine—Bronchitis—Epirubicin—hematologic cancer	0.000121	0.000473	CcSEcCtD
Tolterodine—Hypersensitivity—Alitretinoin—hematologic cancer	0.000121	0.000471	CcSEcCtD
Tolterodine—Flushing—Prednisone—hematologic cancer	0.00012	0.000467	CcSEcCtD
Tolterodine—Headache—Bortezomib—hematologic cancer	0.00012	0.000466	CcSEcCtD
Tolterodine—Pain—Cisplatin—hematologic cancer	0.000119	0.000465	CcSEcCtD
Tolterodine—Hypersensitivity—Ifosfamide—hematologic cancer	0.000119	0.000465	CcSEcCtD
Tolterodine—Asthenia—Carmustine—hematologic cancer	0.000119	0.000463	CcSEcCtD
Tolterodine—Dry mouth—Triamcinolone—hematologic cancer	0.000118	0.000461	CcSEcCtD
Tolterodine—Dysuria—Epirubicin—hematologic cancer	0.000118	0.00046	CcSEcCtD
Tolterodine—Angioedema—Dexamethasone—hematologic cancer	0.000118	0.000459	CcSEcCtD
Tolterodine—Angioedema—Betamethasone—hematologic cancer	0.000118	0.000459	CcSEcCtD
Tolterodine—Diarrhoea—Thalidomide—hematologic cancer	0.000118	0.000459	CcSEcCtD
Tolterodine—Dizziness—Thiotepa—hematologic cancer	0.000118	0.000459	CcSEcCtD
Tolterodine—Asthenia—Alitretinoin—hematologic cancer	0.000118	0.000458	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Epirubicin—hematologic cancer	0.000117	0.000457	CcSEcCtD
Tolterodine—Headache—Vinorelbine—hematologic cancer	0.000117	0.000455	CcSEcCtD
Tolterodine—Hypersensitivity—Vincristine—hematologic cancer	0.000116	0.000453	CcSEcCtD
Tolterodine—Asthenia—Ifosfamide—hematologic cancer	0.000116	0.000453	CcSEcCtD
Tolterodine—Anaphylactic shock—Triamcinolone—hematologic cancer	0.000116	0.000452	CcSEcCtD
Tolterodine—Oedema—Triamcinolone—hematologic cancer	0.000116	0.000452	CcSEcCtD
Tolterodine—Vertigo—Dexamethasone—hematologic cancer	0.000116	0.000452	CcSEcCtD
Tolterodine—Vertigo—Betamethasone—hematologic cancer	0.000116	0.000452	CcSEcCtD
Tolterodine—Infection—Triamcinolone—hematologic cancer	0.000115	0.000449	CcSEcCtD
Tolterodine—Feeling abnormal—Cisplatin—hematologic cancer	0.000115	0.000448	CcSEcCtD
Tolterodine—Weight increased—Epirubicin—hematologic cancer	0.000115	0.000447	CcSEcCtD
Tolterodine—Dizziness—Thalidomide—hematologic cancer	0.000114	0.000444	CcSEcCtD
Tolterodine—Somnolence—Etoposide—hematologic cancer	0.000114	0.000443	CcSEcCtD
Tolterodine—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000113	0.000442	CcSEcCtD
Tolterodine—Hypersensitivity—Irinotecan—hematologic cancer	0.000113	0.000442	CcSEcCtD
Tolterodine—Asthenia—Vincristine—hematologic cancer	0.000113	0.000442	CcSEcCtD
Tolterodine—Tachycardia—Triamcinolone—hematologic cancer	0.000113	0.000441	CcSEcCtD
Tolterodine—Diarrhoea—Carmustine—hematologic cancer	0.000113	0.000441	CcSEcCtD
Tolterodine—Bronchitis—Doxorubicin—hematologic cancer	0.000112	0.000437	CcSEcCtD
Tolterodine—Diarrhoea—Alitretinoin—hematologic cancer	0.000112	0.000437	CcSEcCtD
Tolterodine—Headache—Thiotepa—hematologic cancer	0.000111	0.000435	CcSEcCtD
Tolterodine—Diarrhoea—Ifosfamide—hematologic cancer	0.000111	0.000432	CcSEcCtD
Tolterodine—Asthenia—Irinotecan—hematologic cancer	0.00011	0.00043	CcSEcCtD
Tolterodine—Asthenia—Mitoxantrone—hematologic cancer	0.00011	0.00043	CcSEcCtD
Tolterodine—Fatigue—Etoposide—hematologic cancer	0.00011	0.00043	CcSEcCtD
Tolterodine—Anxiety—Dexamethasone—hematologic cancer	0.000109	0.000427	CcSEcCtD
Tolterodine—Anxiety—Betamethasone—hematologic cancer	0.000109	0.000427	CcSEcCtD
Tolterodine—Dizziness—Carmustine—hematologic cancer	0.000109	0.000426	CcSEcCtD
Tolterodine—Constipation—Etoposide—hematologic cancer	0.000109	0.000426	CcSEcCtD
Tolterodine—Pain—Etoposide—hematologic cancer	0.000109	0.000426	CcSEcCtD
Tolterodine—Urinary tract infection—Epirubicin—hematologic cancer	0.000109	0.000426	CcSEcCtD
Tolterodine—Dysuria—Doxorubicin—hematologic cancer	0.000109	0.000425	CcSEcCtD
Tolterodine—Upper respiratory tract infection—Doxorubicin—hematologic cancer	0.000108	0.000423	CcSEcCtD
Tolterodine—Dizziness—Alitretinoin—hematologic cancer	0.000108	0.000422	CcSEcCtD
Tolterodine—Diarrhoea—Vincristine—hematologic cancer	0.000108	0.000421	CcSEcCtD
Tolterodine—Headache—Thalidomide—hematologic cancer	0.000108	0.000421	CcSEcCtD
Tolterodine—Pain—Prednisolone—hematologic cancer	0.000108	0.00042	CcSEcCtD
Tolterodine—Asthenia—Gemcitabine—hematologic cancer	0.000107	0.000419	CcSEcCtD
Tolterodine—Dizziness—Ifosfamide—hematologic cancer	0.000107	0.000417	CcSEcCtD
Tolterodine—Weight increased—Doxorubicin—hematologic cancer	0.000106	0.000414	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	0.000106	0.000412	CcSEcCtD
Tolterodine—Sinusitis—Epirubicin—hematologic cancer	0.000105	0.000411	CcSEcCtD
Tolterodine—Feeling abnormal—Etoposide—hematologic cancer	0.000105	0.000411	CcSEcCtD
Tolterodine—Oedema—Betamethasone—hematologic cancer	0.000105	0.00041	CcSEcCtD
Tolterodine—Anaphylactic shock—Betamethasone—hematologic cancer	0.000105	0.00041	CcSEcCtD
Tolterodine—Anaphylactic shock—Dexamethasone—hematologic cancer	0.000105	0.00041	CcSEcCtD
Tolterodine—Oedema—Dexamethasone—hematologic cancer	0.000105	0.00041	CcSEcCtD
Tolterodine—Diarrhoea—Mitoxantrone—hematologic cancer	0.000105	0.00041	CcSEcCtD
Tolterodine—Diarrhoea—Irinotecan—hematologic cancer	0.000105	0.00041	CcSEcCtD
Tolterodine—Gastrointestinal pain—Etoposide—hematologic cancer	0.000105	0.000408	CcSEcCtD
Tolterodine—Infection—Betamethasone—hematologic cancer	0.000105	0.000408	CcSEcCtD
Tolterodine—Infection—Dexamethasone—hematologic cancer	0.000105	0.000408	CcSEcCtD
Tolterodine—Dizziness—Vincristine—hematologic cancer	0.000104	0.000407	CcSEcCtD
Tolterodine—Feeling abnormal—Prednisolone—hematologic cancer	0.000104	0.000405	CcSEcCtD
Tolterodine—Visual impairment—Methotrexate—hematologic cancer	0.000104	0.000405	CcSEcCtD
Tolterodine—Headache—Carmustine—hematologic cancer	0.000104	0.000404	CcSEcCtD
Tolterodine—Hypersensitivity—Cisplatin—hematologic cancer	0.000103	0.000401	CcSEcCtD
Tolterodine—Tachycardia—Dexamethasone—hematologic cancer	0.000103	0.0004	CcSEcCtD
Tolterodine—Tachycardia—Betamethasone—hematologic cancer	0.000103	0.0004	CcSEcCtD
Tolterodine—Headache—Alitretinoin—hematologic cancer	0.000103	0.0004	CcSEcCtD
Tolterodine—Angioedema—Prednisone—hematologic cancer	0.000103	0.0004	CcSEcCtD
Tolterodine—Diarrhoea—Gemcitabine—hematologic cancer	0.000102	0.000399	CcSEcCtD
Tolterodine—Dyspepsia—Triamcinolone—hematologic cancer	0.000102	0.000398	CcSEcCtD
Tolterodine—Dizziness—Irinotecan—hematologic cancer	0.000102	0.000396	CcSEcCtD
Tolterodine—Abdominal pain—Etoposide—hematologic cancer	0.000101	0.000394	CcSEcCtD
Tolterodine—Urinary tract infection—Doxorubicin—hematologic cancer	0.000101	0.000394	CcSEcCtD
Tolterodine—Vertigo—Prednisone—hematologic cancer	0.000101	0.000393	CcSEcCtD
Tolterodine—Asthenia—Cisplatin—hematologic cancer	0.0001	0.00039	CcSEcCtD
Tolterodine—Fatigue—Triamcinolone—hematologic cancer	0.0001	0.00039	CcSEcCtD
Tolterodine—Oedema peripheral—Epirubicin—hematologic cancer	9.94e-05	0.000387	CcSEcCtD
Tolterodine—Pain—Triamcinolone—hematologic cancer	9.92e-05	0.000387	CcSEcCtD
Tolterodine—Headache—Vincristine—hematologic cancer	9.89e-05	0.000386	CcSEcCtD
Tolterodine—Sinusitis—Doxorubicin—hematologic cancer	9.75e-05	0.00038	CcSEcCtD
Tolterodine—Visual impairment—Epirubicin—hematologic cancer	9.72e-05	0.000379	CcSEcCtD
Tolterodine—Headache—Mitoxantrone—hematologic cancer	9.63e-05	0.000375	CcSEcCtD
Tolterodine—Headache—Irinotecan—hematologic cancer	9.63e-05	0.000375	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	9.59e-05	0.000374	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	9.59e-05	0.000374	CcSEcCtD
Tolterodine—Arthralgia—Prednisone—hematologic cancer	9.56e-05	0.000373	CcSEcCtD
Tolterodine—Feeling abnormal—Triamcinolone—hematologic cancer	9.56e-05	0.000373	CcSEcCtD
Tolterodine—Diarrhoea—Cisplatin—hematologic cancer	9.55e-05	0.000372	CcSEcCtD
Tolterodine—Anxiety—Prednisone—hematologic cancer	9.53e-05	0.000371	CcSEcCtD
Tolterodine—Hypersensitivity—Etoposide—hematologic cancer	9.42e-05	0.000367	CcSEcCtD
Tolterodine—Headache—Gemcitabine—hematologic cancer	9.38e-05	0.000366	CcSEcCtD
Tolterodine—Flushing—Epirubicin—hematologic cancer	9.36e-05	0.000365	CcSEcCtD
Tolterodine—Hypersensitivity—Prednisolone—hematologic cancer	9.29e-05	0.000362	CcSEcCtD
Tolterodine—Dyspepsia—Betamethasone—hematologic cancer	9.26e-05	0.000361	CcSEcCtD
Tolterodine—Dyspepsia—Dexamethasone—hematologic cancer	9.26e-05	0.000361	CcSEcCtD
Tolterodine—Oedema peripheral—Doxorubicin—hematologic cancer	9.19e-05	0.000359	CcSEcCtD
Tolterodine—Asthenia—Etoposide—hematologic cancer	9.17e-05	0.000358	CcSEcCtD
Tolterodine—Oedema—Prednisone—hematologic cancer	9.16e-05	0.000357	CcSEcCtD
Tolterodine—Anaphylactic shock—Prednisone—hematologic cancer	9.16e-05	0.000357	CcSEcCtD
Tolterodine—Infection—Prednisone—hematologic cancer	9.1e-05	0.000355	CcSEcCtD
Tolterodine—Fatigue—Betamethasone—hematologic cancer	9.07e-05	0.000354	CcSEcCtD
Tolterodine—Fatigue—Dexamethasone—hematologic cancer	9.07e-05	0.000354	CcSEcCtD
Tolterodine—Pain—Dexamethasone—hematologic cancer	9e-05	0.000351	CcSEcCtD
Tolterodine—Pain—Betamethasone—hematologic cancer	9e-05	0.000351	CcSEcCtD
Tolterodine—Visual impairment—Doxorubicin—hematologic cancer	8.99e-05	0.000351	CcSEcCtD
Tolterodine—Tachycardia—Prednisone—hematologic cancer	8.94e-05	0.000349	CcSEcCtD
Tolterodine—Diarrhoea—Etoposide—hematologic cancer	8.75e-05	0.000341	CcSEcCtD
Tolterodine—Feeling abnormal—Betamethasone—hematologic cancer	8.67e-05	0.000338	CcSEcCtD
Tolterodine—Feeling abnormal—Dexamethasone—hematologic cancer	8.67e-05	0.000338	CcSEcCtD
Tolterodine—Flushing—Doxorubicin—hematologic cancer	8.66e-05	0.000338	CcSEcCtD
Tolterodine—Flatulence—Epirubicin—hematologic cancer	8.65e-05	0.000337	CcSEcCtD
Tolterodine—Gastrointestinal pain—Dexamethasone—hematologic cancer	8.6e-05	0.000335	CcSEcCtD
Tolterodine—Gastrointestinal pain—Betamethasone—hematologic cancer	8.6e-05	0.000335	CcSEcCtD
Tolterodine—Hypersensitivity—Triamcinolone—hematologic cancer	8.54e-05	0.000333	CcSEcCtD
Tolterodine—Dizziness—Etoposide—hematologic cancer	8.45e-05	0.00033	CcSEcCtD
Tolterodine—Vertigo—Methotrexate—hematologic cancer	8.43e-05	0.000329	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Prednisone—hematologic cancer	8.35e-05	0.000326	CcSEcCtD
Tolterodine—Dizziness—Prednisolone—hematologic cancer	8.34e-05	0.000325	CcSEcCtD
Tolterodine—Asthenia—Triamcinolone—hematologic cancer	8.32e-05	0.000324	CcSEcCtD
Tolterodine—Abdominal pain—Betamethasone—hematologic cancer	8.32e-05	0.000324	CcSEcCtD
Tolterodine—Abdominal pain—Dexamethasone—hematologic cancer	8.32e-05	0.000324	CcSEcCtD
Tolterodine—Dyspepsia—Prednisone—hematologic cancer	8.07e-05	0.000315	CcSEcCtD
Tolterodine—Headache—Etoposide—hematologic cancer	8.01e-05	0.000312	CcSEcCtD
Tolterodine—Flatulence—Doxorubicin—hematologic cancer	8.01e-05	0.000312	CcSEcCtD
Tolterodine—Arthralgia—Methotrexate—hematologic cancer	7.99e-05	0.000311	CcSEcCtD
Tolterodine—Chest pain—Methotrexate—hematologic cancer	7.99e-05	0.000311	CcSEcCtD
Tolterodine—Fatigue—Prednisone—hematologic cancer	7.9e-05	0.000308	CcSEcCtD
Tolterodine—Headache—Prednisolone—hematologic cancer	7.9e-05	0.000308	CcSEcCtD
Tolterodine—Vertigo—Epirubicin—hematologic cancer	7.89e-05	0.000308	CcSEcCtD
Tolterodine—Constipation—Prednisone—hematologic cancer	7.84e-05	0.000306	CcSEcCtD
Tolterodine—Palpitations—Epirubicin—hematologic cancer	7.76e-05	0.000303	CcSEcCtD
Tolterodine—Confusional state—Methotrexate—hematologic cancer	7.72e-05	0.000301	CcSEcCtD
Tolterodine—Dizziness—Triamcinolone—hematologic cancer	7.67e-05	0.000299	CcSEcCtD
Tolterodine—Anaphylactic shock—Methotrexate—hematologic cancer	7.66e-05	0.000299	CcSEcCtD
Tolterodine—Infection—Methotrexate—hematologic cancer	7.61e-05	0.000297	CcSEcCtD
Tolterodine—Feeling abnormal—Prednisone—hematologic cancer	7.55e-05	0.000294	CcSEcCtD
Tolterodine—Asthenia—Dexamethasone—hematologic cancer	7.55e-05	0.000294	CcSEcCtD
Tolterodine—Asthenia—Betamethasone—hematologic cancer	7.55e-05	0.000294	CcSEcCtD
Tolterodine—Gastrointestinal pain—Prednisone—hematologic cancer	7.49e-05	0.000292	CcSEcCtD
Tolterodine—Arthralgia—Epirubicin—hematologic cancer	7.48e-05	0.000292	CcSEcCtD
Tolterodine—Chest pain—Epirubicin—hematologic cancer	7.48e-05	0.000292	CcSEcCtD
Tolterodine—Anxiety—Epirubicin—hematologic cancer	7.45e-05	0.00029	CcSEcCtD
Tolterodine—Dry mouth—Epirubicin—hematologic cancer	7.31e-05	0.000285	CcSEcCtD
Tolterodine—Vertigo—Doxorubicin—hematologic cancer	7.3e-05	0.000285	CcSEcCtD
Tolterodine—Headache—Triamcinolone—hematologic cancer	7.26e-05	0.000283	CcSEcCtD
Tolterodine—Abdominal pain—Prednisone—hematologic cancer	7.24e-05	0.000282	CcSEcCtD
Tolterodine—Confusional state—Epirubicin—hematologic cancer	7.23e-05	0.000282	CcSEcCtD
Tolterodine—Diarrhoea—Betamethasone—hematologic cancer	7.2e-05	0.000281	CcSEcCtD
Tolterodine—Diarrhoea—Dexamethasone—hematologic cancer	7.2e-05	0.000281	CcSEcCtD
Tolterodine—Palpitations—Doxorubicin—hematologic cancer	7.18e-05	0.00028	CcSEcCtD
Tolterodine—Oedema—Epirubicin—hematologic cancer	7.17e-05	0.000279	CcSEcCtD
Tolterodine—Anaphylactic shock—Epirubicin—hematologic cancer	7.17e-05	0.000279	CcSEcCtD
Tolterodine—Infection—Epirubicin—hematologic cancer	7.12e-05	0.000278	CcSEcCtD
Tolterodine—Tachycardia—Epirubicin—hematologic cancer	6.99e-05	0.000273	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	6.98e-05	0.000272	CcSEcCtD
Tolterodine—Dizziness—Dexamethasone—hematologic cancer	6.96e-05	0.000271	CcSEcCtD
Tolterodine—Dizziness—Betamethasone—hematologic cancer	6.96e-05	0.000271	CcSEcCtD
Tolterodine—Chest pain—Doxorubicin—hematologic cancer	6.92e-05	0.00027	CcSEcCtD
Tolterodine—Arthralgia—Doxorubicin—hematologic cancer	6.92e-05	0.00027	CcSEcCtD
Tolterodine—Anxiety—Doxorubicin—hematologic cancer	6.89e-05	0.000269	CcSEcCtD
Tolterodine—Somnolence—Methotrexate—hematologic cancer	6.81e-05	0.000265	CcSEcCtD
Tolterodine—Dry mouth—Doxorubicin—hematologic cancer	6.76e-05	0.000264	CcSEcCtD
Tolterodine—Hypersensitivity—Prednisone—hematologic cancer	6.75e-05	0.000263	CcSEcCtD
Tolterodine—Dyspepsia—Methotrexate—hematologic cancer	6.74e-05	0.000263	CcSEcCtD
Tolterodine—Confusional state—Doxorubicin—hematologic cancer	6.69e-05	0.000261	CcSEcCtD
Tolterodine—Anaphylactic shock—Doxorubicin—hematologic cancer	6.63e-05	0.000259	CcSEcCtD
Tolterodine—Oedema—Doxorubicin—hematologic cancer	6.63e-05	0.000259	CcSEcCtD
Tolterodine—Fatigue—Methotrexate—hematologic cancer	6.6e-05	0.000257	CcSEcCtD
Tolterodine—Headache—Betamethasone—hematologic cancer	6.59e-05	0.000257	CcSEcCtD
Tolterodine—Headache—Dexamethasone—hematologic cancer	6.59e-05	0.000257	CcSEcCtD
Tolterodine—Infection—Doxorubicin—hematologic cancer	6.59e-05	0.000257	CcSEcCtD
Tolterodine—Asthenia—Prednisone—hematologic cancer	6.57e-05	0.000256	CcSEcCtD
Tolterodine—Pain—Methotrexate—hematologic cancer	6.55e-05	0.000255	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	6.53e-05	0.000255	CcSEcCtD
Tolterodine—Tachycardia—Doxorubicin—hematologic cancer	6.47e-05	0.000252	CcSEcCtD
Tolterodine—Somnolence—Epirubicin—hematologic cancer	6.37e-05	0.000248	CcSEcCtD
Tolterodine—Feeling abnormal—Methotrexate—hematologic cancer	6.31e-05	0.000246	CcSEcCtD
Tolterodine—Dyspepsia—Epirubicin—hematologic cancer	6.31e-05	0.000246	CcSEcCtD
Tolterodine—Diarrhoea—Prednisone—hematologic cancer	6.27e-05	0.000244	CcSEcCtD
Tolterodine—Gastrointestinal pain—Methotrexate—hematologic cancer	6.26e-05	0.000244	CcSEcCtD
Tolterodine—Fatigue—Epirubicin—hematologic cancer	6.18e-05	0.000241	CcSEcCtD
Tolterodine—Pain—Epirubicin—hematologic cancer	6.13e-05	0.000239	CcSEcCtD
Tolterodine—Constipation—Epirubicin—hematologic cancer	6.13e-05	0.000239	CcSEcCtD
Tolterodine—Dizziness—Prednisone—hematologic cancer	6.06e-05	0.000236	CcSEcCtD
Tolterodine—Abdominal pain—Methotrexate—hematologic cancer	6.05e-05	0.000236	CcSEcCtD
Tolterodine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	6.04e-05	0.000236	CcSEcCtD
Tolterodine—Feeling abnormal—Epirubicin—hematologic cancer	5.91e-05	0.00023	CcSEcCtD
Tolterodine—Somnolence—Doxorubicin—hematologic cancer	5.89e-05	0.00023	CcSEcCtD
Tolterodine—Gastrointestinal pain—Epirubicin—hematologic cancer	5.86e-05	0.000229	CcSEcCtD
Tolterodine—Dyspepsia—Doxorubicin—hematologic cancer	5.84e-05	0.000228	CcSEcCtD
Tolterodine—Headache—Prednisone—hematologic cancer	5.74e-05	0.000224	CcSEcCtD
Tolterodine—Fatigue—Doxorubicin—hematologic cancer	5.72e-05	0.000223	CcSEcCtD
Tolterodine—Pain—Doxorubicin—hematologic cancer	5.67e-05	0.000221	CcSEcCtD
Tolterodine—Constipation—Doxorubicin—hematologic cancer	5.67e-05	0.000221	CcSEcCtD
Tolterodine—Abdominal pain—Epirubicin—hematologic cancer	5.66e-05	0.000221	CcSEcCtD
Tolterodine—Hypersensitivity—Methotrexate—hematologic cancer	5.64e-05	0.00022	CcSEcCtD
Tolterodine—Asthenia—Methotrexate—hematologic cancer	5.49e-05	0.000214	CcSEcCtD
Tolterodine—Feeling abnormal—Doxorubicin—hematologic cancer	5.46e-05	0.000213	CcSEcCtD
Tolterodine—Gastrointestinal pain—Doxorubicin—hematologic cancer	5.42e-05	0.000211	CcSEcCtD
Tolterodine—Hypersensitivity—Epirubicin—hematologic cancer	5.28e-05	0.000206	CcSEcCtD
Tolterodine—Abdominal pain—Doxorubicin—hematologic cancer	5.24e-05	0.000204	CcSEcCtD
Tolterodine—Diarrhoea—Methotrexate—hematologic cancer	5.24e-05	0.000204	CcSEcCtD
Tolterodine—Asthenia—Epirubicin—hematologic cancer	5.14e-05	0.0002	CcSEcCtD
Tolterodine—Dizziness—Methotrexate—hematologic cancer	5.06e-05	0.000197	CcSEcCtD
Tolterodine—Diarrhoea—Epirubicin—hematologic cancer	4.9e-05	0.000191	CcSEcCtD
Tolterodine—Hypersensitivity—Doxorubicin—hematologic cancer	4.89e-05	0.000191	CcSEcCtD
Tolterodine—Headache—Methotrexate—hematologic cancer	4.8e-05	0.000187	CcSEcCtD
Tolterodine—Asthenia—Doxorubicin—hematologic cancer	4.76e-05	0.000186	CcSEcCtD
Tolterodine—Dizziness—Epirubicin—hematologic cancer	4.74e-05	0.000185	CcSEcCtD
Tolterodine—Diarrhoea—Doxorubicin—hematologic cancer	4.54e-05	0.000177	CcSEcCtD
Tolterodine—Headache—Epirubicin—hematologic cancer	4.49e-05	0.000175	CcSEcCtD
Tolterodine—Dizziness—Doxorubicin—hematologic cancer	4.38e-05	0.000171	CcSEcCtD
Tolterodine—Headache—Doxorubicin—hematologic cancer	4.15e-05	0.000162	CcSEcCtD
Tolterodine—CHRM1—Signaling Pathways—KIT—hematologic cancer	5.1e-06	5.28e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	5.1e-06	5.28e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL2—hematologic cancer	5.1e-06	5.28e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CD80—hematologic cancer	5.09e-06	5.27e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	5.08e-06	5.26e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KIT—hematologic cancer	5.08e-06	5.26e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	5.08e-06	5.26e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—IL6—hematologic cancer	5.07e-06	5.25e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3R1—hematologic cancer	5.05e-06	5.23e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CD80—hematologic cancer	5.04e-06	5.22e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ABCB1—hematologic cancer	5.04e-06	5.22e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CG—hematologic cancer	5.03e-06	5.21e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KIT—hematologic cancer	5.03e-06	5.21e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—NRAS—hematologic cancer	5.03e-06	5.21e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTT1—hematologic cancer	5.02e-06	5.2e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—CDKN1A—hematologic cancer	5.02e-06	5.2e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	5.01e-06	5.19e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PTEN—hematologic cancer	5.01e-06	5.19e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ABCB1—hematologic cancer	5e-06	5.18e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	4.99e-06	5.17e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CCND1—hematologic cancer	4.97e-06	5.15e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—JUN—hematologic cancer	4.96e-06	5.14e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTPN11—hematologic cancer	4.94e-06	5.12e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—SDC1—hematologic cancer	4.91e-06	5.09e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK8—hematologic cancer	4.9e-06	5.07e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—GSTM1—hematologic cancer	4.89e-06	5.07e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—NCOR1—hematologic cancer	4.89e-06	5.07e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling by GPCR—AKT1—hematologic cancer	4.88e-06	5.06e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	4.88e-06	5.06e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	4.87e-06	5.04e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CREB1—hematologic cancer	4.85e-06	5.03e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—NCOR1—hematologic cancer	4.85e-06	5.03e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—GSTM1—hematologic cancer	4.85e-06	5.03e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CREB1—hematologic cancer	4.84e-06	5.01e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—MAPK3—hematologic cancer	4.82e-06	4.99e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—CDKN1A—hematologic cancer	4.81e-06	4.98e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PTEN—hematologic cancer	4.79e-06	4.97e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—BRAF—hematologic cancer	4.79e-06	4.96e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CREB1—hematologic cancer	4.79e-06	4.96e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—BRAF—hematologic cancer	4.78e-06	4.95e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—EP300—hematologic cancer	4.77e-06	4.95e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCL2—hematologic cancer	4.75e-06	4.92e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6R—hematologic cancer	4.73e-06	4.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCL2—hematologic cancer	4.73e-06	4.9e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—BRAF—hematologic cancer	4.73e-06	4.9e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	4.73e-06	4.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6R—hematologic cancer	4.72e-06	4.89e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	4.71e-06	4.88e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—MTHFR—hematologic cancer	4.7e-06	4.87e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK8—hematologic cancer	4.69e-06	4.86e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCL2—hematologic cancer	4.69e-06	4.86e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling by GPCR—AKT1—hematologic cancer	4.68e-06	4.85e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6R—hematologic cancer	4.67e-06	4.84e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CREBBP—hematologic cancer	4.67e-06	4.83e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CB—hematologic cancer	4.66e-06	4.82e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—SRC—hematologic cancer	4.64e-06	4.81e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—EP300—hematologic cancer	4.57e-06	4.74e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—VEGFA—hematologic cancer	4.52e-06	4.68e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	4.51e-06	4.67e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	4.5e-06	4.66e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	4.48e-06	4.64e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—STAT3—hematologic cancer	4.48e-06	4.64e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	4.47e-06	4.63e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—NRAS—hematologic cancer	4.47e-06	4.63e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAP2K1—hematologic cancer	4.45e-06	4.61e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—SRC—hematologic cancer	4.45e-06	4.61e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	4.44e-06	4.6e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	4.43e-06	4.58e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CD—hematologic cancer	4.42e-06	4.58e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	4.39e-06	4.55e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—PIK3CA—hematologic cancer	4.38e-06	4.54e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	4.37e-06	4.53e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—KRAS—hematologic cancer	4.33e-06	4.49e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—VEGFA—hematologic cancer	4.33e-06	4.49e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—MTHFR—hematologic cancer	4.33e-06	4.48e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—FGF2—hematologic cancer	4.29e-06	4.45e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—MTHFR—hematologic cancer	4.29e-06	4.44e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—STAT3—hematologic cancer	4.29e-06	4.44e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MAPK3—hematologic cancer	4.28e-06	4.43e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—FGF2—hematologic cancer	4.28e-06	4.43e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—NRAS—hematologic cancer	4.28e-06	4.43e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—FGF2—hematologic cancer	4.24e-06	4.39e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	4.23e-06	4.38e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	4.22e-06	4.37e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3R1—hematologic cancer	4.18e-06	4.33e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NQO1—hematologic cancer	4.17e-06	4.33e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CD44—hematologic cancer	4.17e-06	4.33e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—MYC—hematologic cancer	4.16e-06	4.31e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TGFB1—hematologic cancer	4.15e-06	4.3e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.14e-06	4.29e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JAK2—hematologic cancer	4.11e-06	4.26e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JAK2—hematologic cancer	4.1e-06	4.25e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MAPK3—hematologic cancer	4.1e-06	4.24e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JAK2—hematologic cancer	4.06e-06	4.21e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	4.03e-06	4.18e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PTEN—hematologic cancer	4.02e-06	4.17e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	4.02e-06	4.16e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MDM2—hematologic cancer	4.02e-06	4.16e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MDM2—hematologic cancer	4e-06	4.15e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—MYC—hematologic cancer	3.98e-06	4.13e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—PIK3CA—hematologic cancer	3.98e-06	4.12e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TGFB1—hematologic cancer	3.97e-06	4.12e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MDM2—hematologic cancer	3.96e-06	4.11e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CG—hematologic cancer	3.95e-06	4.09e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CYCS—hematologic cancer	3.95e-06	4.09e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	3.93e-06	4.07e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	3.91e-06	4.05e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MTOR—hematologic cancer	3.91e-06	4.05e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	3.89e-06	4.03e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MTOR—hematologic cancer	3.89e-06	4.03e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MTOR—hematologic cancer	3.86e-06	4e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CB—hematologic cancer	3.86e-06	4e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—KRAS—hematologic cancer	3.84e-06	3.98e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—EP300—hematologic cancer	3.84e-06	3.98e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.78e-06	3.91e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	3.73e-06	3.86e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	3.72e-06	3.85e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—HRAS—hematologic cancer	3.68e-06	3.81e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—KRAS—hematologic cancer	3.68e-06	3.81e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	3.67e-06	3.8e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—CREBBP—hematologic cancer	3.66e-06	3.8e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	3.65e-06	3.79e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	3.63e-06	3.76e-05	CbGpPWpGaD
Tolterodine—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	3.63e-06	3.76e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1B—hematologic cancer	3.62e-06	3.75e-05	CbGpPWpGaD
Tolterodine—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	3.62e-06	3.75e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CG—hematologic cancer	3.6e-06	3.73e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CASP3—hematologic cancer	3.59e-06	3.72e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL2—hematologic cancer	3.59e-06	3.72e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CASP3—hematologic cancer	3.58e-06	3.71e-05	CbGpPWpGaD
Tolterodine—CHRM2—GPCR downstream signaling—AKT1—hematologic cancer	3.58e-06	3.71e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL2—hematologic cancer	3.58e-06	3.71e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—IL6—hematologic cancer	3.57e-06	3.7e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—IL6—hematologic cancer	3.56e-06	3.69e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CASP3—hematologic cancer	3.55e-06	3.67e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL2—hematologic cancer	3.54e-06	3.67e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—PIK3CA—hematologic cancer	3.53e-06	3.66e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—IL6—hematologic cancer	3.52e-06	3.65e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CCND1—hematologic cancer	3.5e-06	3.62e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—JUN—hematologic cancer	3.49e-06	3.62e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CCND1—hematologic cancer	3.49e-06	3.61e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTP1—hematologic cancer	3.48e-06	3.61e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—JUN—hematologic cancer	3.48e-06	3.6e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CD—hematologic cancer	3.47e-06	3.6e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CCND1—hematologic cancer	3.45e-06	3.58e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—JUN—hematologic cancer	3.45e-06	3.57e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—ALB—hematologic cancer	3.43e-06	3.55e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—TP53—hematologic cancer	3.42e-06	3.54e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	3.38e-06	3.51e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—PIK3CA—hematologic cancer	3.38e-06	3.5e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PTEN—hematologic cancer	3.38e-06	3.5e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	3.37e-06	3.49e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—CREBBP—hematologic cancer	3.37e-06	3.49e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PTEN—hematologic cancer	3.37e-06	3.49e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—CREBBP—hematologic cancer	3.34e-06	3.46e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—CDKN1A—hematologic cancer	3.34e-06	3.46e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PTEN—hematologic cancer	3.33e-06	3.45e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	3.3e-06	3.42e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ABCB1—hematologic cancer	3.3e-06	3.41e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	3.29e-06	3.41e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	3.29e-06	3.41e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	3.28e-06	3.4e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3R1—hematologic cancer	3.28e-06	3.4e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—TP53—hematologic cancer	3.27e-06	3.39e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—HRAS—hematologic cancer	3.27e-06	3.39e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK8—hematologic cancer	3.26e-06	3.38e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling by GPCR—AKT1—hematologic cancer	3.25e-06	3.37e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—EP300—hematologic cancer	3.22e-06	3.34e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—EP300—hematologic cancer	3.21e-06	3.32e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—NCOR1—hematologic cancer	3.2e-06	3.31e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—GSTM1—hematologic cancer	3.2e-06	3.31e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	3.19e-06	3.31e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—EP300—hematologic cancer	3.18e-06	3.29e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CD—hematologic cancer	3.17e-06	3.28e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—ALB—hematologic cancer	3.15e-06	3.27e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—SRC—hematologic cancer	3.13e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—HRAS—hematologic cancer	3.13e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—IL6—hematologic cancer	3.13e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—ALB—hematologic cancer	3.13e-06	3.24e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—SRC—hematologic cancer	3.12e-06	3.23e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—SRC—hematologic cancer	3.09e-06	3.2e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	3.05e-06	3.16e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	3.04e-06	3.15e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CB—hematologic cancer	3.03e-06	3.14e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—STAT3—hematologic cancer	3.02e-06	3.13e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	3.02e-06	3.13e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—NRAS—hematologic cancer	3.01e-06	3.12e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—VEGFA—hematologic cancer	3.01e-06	3.12e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—STAT3—hematologic cancer	3.01e-06	3.12e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—NRAS—hematologic cancer	3e-06	3.11e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—IL6—hematologic cancer	3e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3R1—hematologic cancer	2.99e-06	3.1e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—STAT3—hematologic cancer	2.98e-06	3.09e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—NRAS—hematologic cancer	2.97e-06	3.08e-05	CbGpPWpGaD
Tolterodine—CHRM4—Signaling Pathways—AKT1—hematologic cancer	2.89e-06	2.99e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	2.88e-06	2.99e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	2.88e-06	2.98e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MAPK3—hematologic cancer	2.85e-06	2.95e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—PIK3CA—hematologic cancer	2.84e-06	2.94e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—MTHFR—hematologic cancer	2.83e-06	2.93e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—MYC—hematologic cancer	2.81e-06	2.91e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	2.8e-06	2.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—MYC—hematologic cancer	2.8e-06	2.9e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	2.79e-06	2.89e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	2.78e-06	2.88e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—MYC—hematologic cancer	2.77e-06	2.87e-05	CbGpPWpGaD
Tolterodine—CHRM5—Signaling Pathways—AKT1—hematologic cancer	2.76e-06	2.86e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TGFB1—hematologic cancer	2.76e-06	2.86e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CB—hematologic cancer	2.76e-06	2.86e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PTEN—hematologic cancer	2.62e-06	2.71e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—KRAS—hematologic cancer	2.59e-06	2.69e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—KRAS—hematologic cancer	2.58e-06	2.68e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—KRAS—hematologic cancer	2.56e-06	2.65e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—EP300—hematologic cancer	2.49e-06	2.58e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PTEN—hematologic cancer	2.41e-06	2.49e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PTEN—hematologic cancer	2.39e-06	2.47e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	2.38e-06	2.47e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	2.38e-06	2.46e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	2.37e-06	2.46e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—PIK3CA—hematologic cancer	2.35e-06	2.44e-05	CbGpPWpGaD
Tolterodine—CHRM3—Metabolism—AKT1—hematologic cancer	2.32e-06	2.4e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—TP53—hematologic cancer	2.3e-06	2.39e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—TP53—hematologic cancer	2.3e-06	2.38e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—EP300—hematologic cancer	2.29e-06	2.38e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—EP300—hematologic cancer	2.27e-06	2.36e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—TP53—hematologic cancer	2.27e-06	2.36e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—HRAS—hematologic cancer	2.2e-06	2.28e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—CREBBP—hematologic cancer	2.2e-06	2.28e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—HRAS—hematologic cancer	2.2e-06	2.28e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—HRAS—hematologic cancer	2.17e-06	2.25e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—IL6—hematologic cancer	2.11e-06	2.18e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—IL6—hematologic cancer	2.1e-06	2.18e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	2.09e-06	2.16e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—IL6—hematologic cancer	2.08e-06	2.16e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—ALB—hematologic cancer	2.06e-06	2.14e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.97e-06	2.04e-05	CbGpPWpGaD
Tolterodine—CHRM1—Signaling Pathways—AKT1—hematologic cancer	1.95e-06	2.02e-05	CbGpPWpGaD
Tolterodine—CHRM3—Signaling Pathways—AKT1—hematologic cancer	1.94e-06	2.01e-05	CbGpPWpGaD
Tolterodine—CHRM2—Signaling Pathways—AKT1—hematologic cancer	1.92e-06	1.99e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—PIK3CA—hematologic cancer	1.85e-06	1.91e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.82e-06	1.89e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	1.7e-06	1.76e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—PIK3CA—hematologic cancer	1.68e-06	1.74e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PTEN—hematologic cancer	1.57e-06	1.63e-05	CbGpPWpGaD
Tolterodine—CYP2C19—Metabolism—AKT1—hematologic cancer	1.51e-06	1.56e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—EP300—hematologic cancer	1.5e-06	1.55e-05	CbGpPWpGaD
Tolterodine—CYP2D6—Metabolism—AKT1—hematologic cancer	1.39e-06	1.44e-05	CbGpPWpGaD
Tolterodine—CYP2C9—Metabolism—AKT1—hematologic cancer	1.37e-06	1.42e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	1.11e-06	1.15e-05	CbGpPWpGaD
Tolterodine—CYP3A4—Metabolism—AKT1—hematologic cancer	9.07e-07	9.39e-06	CbGpPWpGaD
